2. Search Result
Search Result
Results for "

cis-platin

" in MedChemExpress (MCE) Product Catalog:

95

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

3

Peptides

15

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17394
    Cisplatin
    Maximum Cited Publications
    545 Publications Verification

    cis-platinum; CDDP; cis-Diaminodichloroplatinum

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-44307
    84-B10

    		Ferroptosis Cancer
    84-B10 is a 3-phenylglutaric acid derivative. 84-B10 inhibits cisplatin (HY-17394) induced tubular ferroptosis. 84-B10 attenuates cisplatin-induced mitochondrial damage and oxidative stress. 84-B10 ameliorates cisplatin-induced acute kidney injury (AKI) .
    84-B10
  • HY-13700
    Nedaplatin
    1 Publications Verification

    NSC 375101D

    		 DNA/RNA Synthesis Cancer
    Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
    Nedaplatin
  • HY-161687
    Cisplatin/Dasatinib prodrug-1

    		Src Cancer
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .
    Cisplatin/Dasatinib prodrug-1
  • HY-154978
    Cisplatin-resistant cells-IN-1

    		Others Cancer
    Cisplatin-resistant cells-IN-1 (Compound 8) has high cytotoxicity against Cisplatin (HY-17394)-resistant cells. Cisplatin-resistant cells-IN-1 reduces the metabolic activity effectively in the low nanomolar range (IC50: 0.14–1.79 μM in A549/A549-R, K562/K562-R, and MCF-7/MCF-7TamR cells) .
    Cisplatin-resistant cells-IN-1
  • HY-N15306
    Boerelasin E

    		Apoptosis Cancer
    Boerelasin E is the first cytochalasan possessing a cis-configured Δ21(22) double bond that can be isolated from endophytic fungus Boeremia exigua. Boerelasin E exhibits antiproliferative activity against MCF-7 cells (IC50=20.52 μM) more potent than cisplatin (HY-17394). Boerelasin E inhibits the complete cell division of MCF-7 cells by arresting them in the G2/M phase and inducing apoptosis[1].
    Boerelasin E
  • HY-162410
    Fluplatin

    		MDM-2/p53 Cancer
    Fluplatin is a prodrug composed of cisplatin and fluvastatin. Fluplatin has antitumor activity .
    Fluplatin
  • HY-105890
    Spiroplatin

    TNO 6

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Spiroplatin is a Cisplatin (HY-17394) congener and has antitumor activity .
    Spiroplatin
  • HY-N2757
    7-Ketositosterol

    		Apoptosis Cancer
    7-Ketositosterol is a phytosterol isolated from the fruits of the mulberry tree (Morus alba L.). 7-Ketositosterol can significantly inhibit Cisplatin (HY-17394)-induced apoptosis in LLC-PK1 cells and has the potential to improve Cisplatin-induced nephrotoxicity .
    7-Ketositosterol
  • HY-171447
    LPT99

    		Caspase Apoptosis Others
    LPT-99 is an antagonist of apoptotic protease activating factor 1 (APAF-1). LPT-99 suppresses the activation of procaspase-9. LPT99 suppresses Cisplatin (HY-17394)-induced apoptosis. LPT99 can effectively mitigate cisplatin-induced hearing loss in rats.
    LPT99
  • HY-161661
    Anticancer agent 223

    		Others Cancer
    Anticancer agent 223 (Compound V-d) is an anticancer agent that triggers cell death through caspase-dependent and caspase-independent mechanisms. Anticancer agent 223 inhibits tumor spheroid formation and resensitizes cisplatin (HY-17394)-resistant A2780 cells to cisplatin (HY-17394) treatment .
    Anticancer agent 223
  • HY-113636
    Kazinol A

    		Apoptosis Autophagy Akt AMPK Cancer
    Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .
    Kazinol A
  • HY-163506
    Ebselen derivative 1

    		Apoptosis Ferroptosis Others
    Ebselen derivative 1 (Compound 19) is a glutathione peroxidase (GPx) mimic with oral activity. Ebselen derivative 1 demonstrates significant protective effects against cisplatin (HY-17394)-induced hair cell (HC) damage both in vitro and in vivo, effectively reducing oxidative stress, apoptosis, and ferroptosis in hair cells. Ebselen derivative 1 can be utilized in the research of cisplatin (HY-17394)-induced hearing loss .
    Ebselen derivative 1
  • HY-173064
    DS-103

    		HDAC Parasite Infection Cancer
    DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin (HY-17394) resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis .
    DS-103
  • HY-101255
    ODQ
    3 Publications Verification

    		 Guanylate Cyclase Apoptosis Cancer
    ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .
    ODQ
  • HY-146194
    NHEJ inhibitor-1

    		Reactive Oxygen Species Cancer
    NHEJ inhibitor-1 (Compound C2) is a trifunctional Pt(II) complex, alleviates the non-homologous end connection (NHEJ)/homologous recombination (HR)-related double strand breaks (DSBs) repairs to evade Cisplatin-resistance in non-small cell lung cancer (NSCLC). NHEJ inhibitor-1 inhibits the damage repair proteins Ku70 and Rad51 to make tumors re-sensitive to Cisplatin. NHEJ inhibitor-1 also induces ROS generation and MMP deduction .
    NHEJ inhibitor-1
  • HY-D2438
    CDDP-PEG-Cy3

    		Fluorescent Dye Cancer
    CDDP-PEG-Cy3 is a CDDP-PEG conjugate labeled with Cy3 (HY-D0822). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Cisplatin (CDDP) (HY-17394) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    CDDP-PEG-Cy3
  • HY-B0639C
    Amifostine sodium

    WR2721 sodium

    		 MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Neurological Disease
    Amifostine sodium (WR2721 sodium) is a phosphorus sulfate with radioprotective activity. Amifostine sodium can cause splenic vasodilation and may block autonomic ganglia. Amifostine sodium is clinically used to prevent cisplatin-induced ototoxicity .
    Amifostine sodium
  • HY-128064
    Adenosine amine congener

    ADAC

    		 Adenosine Receptor Neurological Disease Inflammation/Immunology
    Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects .
    Adenosine amine congener
  • HY-B0019C
    (R)-Azasetron besylate

    SENS-401

    		 Phosphatase Cancer
    (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage .
    (R)-Azasetron besylate
  • HY-116392B
    DL-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .
    DL-threo-PDMP hydrochloride
  • HY-14919A
    Denibulin hydrochloride

    MN-029

    		 Microtubule/Tubulin Cancer
    Denibulin (MN-029) hydrochloride is an anti-angiogenic agent with anticancer activity. It can cause rapid closure of blood vessels in solid tumors and lead to dose-dependent killing of tumor cells, effectively enhancing the antitumor effects of radiation and cisplatin chemotherapy .
    Denibulin hydrochloride
  • HY-111253
    CYM-5478

    		LPL Receptor Neurological Disease
    CYM-5478 is a potent and highly selective S1P2 agonist with an EC50 of 119 nM in a TGFα-shedding assay. CYM-5478 protects neural-derived cell lines against Cisplatin toxicity .
    CYM-5478
  • HY-129677
    ORC-13661 hydrochloride

    		TRP Channel Others
    ORC-13661 hydrochloride is a hair cell protector. ORC-13661 hydrochloride protects sensory hair cells from aminoglycoside and Cisplatin (HY-17394) ototoxicity. ORC-13661 hydrochloride is a reversibly mechanoelectrical transducer (MET) channel permeant blocker .
    ORC-13661 hydrochloride
  • HY-19536
    LLL12

    		STAT Cancer
    LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .
    LLL12
  • HY-101255R
    ODQ (Standard)

    		Guanylate Cyclase Apoptosis Cancer
    ODQ (Standard) is the analytical standard of ODQ. This product is intended for research and analytical applications. ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells[1].
    ODQ (Standard)
  • HY-106588
    Heptaplatin

    SKI 2053R

    		 DNA Alkylator/Crosslinker Cancer
    Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .
    Heptaplatin
  • HY-163748
    GSK-3β inhibitor 17

    		GSK-3 Inflammation/Immunology
    GSK-3β inhibitor 17 (compound 5 n) is a potent GSK-3β inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .
    GSK-3β inhibitor 17
  • HY-131553
    D-α-Tocopherol Succinate
    3 Publications Verification

    Vitamin E succinate

    		 Apoptosis Cancer
    D-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer .
    D-α-Tocopherol Succinate
  • HY-121608
    Lumiflavin

    Lumiflavine

    		 Fluorescent Dye Notch Cancer
    Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer .
    Lumiflavin
  • HY-N3847
    Eriodictyol-7-O-glucoside

    Eriodictyol 7-O-β-D-glucoside

    		 Keap1-Nrf2 Metabolic Disease
    Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is a potent free radical scavenger. Eriodictyol-7-O-glucoside is also an Nrf2 activator, confers protection against Cisplatin-induced toxicity .
    Eriodictyol-7-O-glucoside
  • HY-149508
    Nrf2-IN-3

    		Keap1-Nrf2 Reactive Oxygen Species Cancer
    Nrf2-IN-3 (Compound R16) is a small-molecule NRF2 inhibitor and increases reactive oxygen species (ROS) production. Nrf2-IN-3 selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions, leading to proteasome-dependent NRF2 degradation in cells. Nrf2-IN-3 sensitizes KEAP1-mutated tumor cells to Cisplatin (HY-17394), Gefitinib (HY-50895), and KEAP1 G333C-mutated xenograft to Cisplatin .
    Nrf2-IN-3
  • HY-13816
    NU6027

    		CDK ATM/ATR Cancer
    NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
    NU6027
  • HY-D2452
    Cy3-Ccisplatin

    		Fluorescent Dye Others
    Cy3-Ccisplatin is a compound of Cyanine 3 fluorescent dye CY3 (HY-D0822) combined with Cisplatin (HY-17394). Cy3-Ccisplatin can be used for drug delivery, fluorescent labeling, cell imaging and tracking .
    Cy3-Ccisplatin
  • HY-106889
    Zelandopam free base

    YM435 free base

    		 Dopamine Receptor Others
    Zelandopam free base (YM435 free base) is an orally active and selective agonist of the dopamine D1 receptor. Zelandopam free base possesses potent renal vasodilatory properties and can effectively alleviate cisplatin (HY-17394)-induced acute renal failure .
    Zelandopam free base
  • HY-147356
    ERCC1-XPF-IN-2

    		DNA/RNA Synthesis Cancer
    ERCC1-XPF-IN-2 is a potent ERCC1-XPF endonuclease inhibitor with an IC50 value of 0.6 µM. ERCC1-XPF-IN-2 shows activity in nucleotide excision repair, cisplatin enhancement and γH2AX assays .
    ERCC1-XPF-IN-2
  • HY-163323
    AKR1C3-IN-12

    		Aldose Reductase Cancer
    AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .
    AKR1C3-IN-12
  • HY-117082
    UTL-5g

    GBL-5g

    		 TNF Receptor Inflammation/Immunology
    UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors .
    UTL-5g
  • HY-N10313
    Dehydrobruceine B

    		Bcl-2 Family Keap1-Nrf2 Apoptosis Cancer
    Dehydrobruceine B, a quassinoid, can be isolated from Brucea javanica. Dehydrobruceine B shows a synergistic effect with Cisplatin (HY-17394) to induce apoptosis via mitochondrial method. Dehydrobruceine B increases apoptosis-inducing factor (AIF) and Bax expression and suppresses Keap1-Nrf2 .
    Dehydrobruceine B
  • HY-168711
    P-gp inhibitor 27

    		P-glycoprotein Cancer
    P-gp inhibitor 27 (Compound D2) is an inhibitor for P-glycoprotein (P-gp), that downregulates the expression of P-gp and MRP1, increases the Rh123 accumulation in A2780/T cell, and reverses multidrug resistance to Paclitaxel (HY-B0015) (EC50 is 88 nM) and Cisplatin (HY-17394) .
    P-gp inhibitor 27
  • HY-139696
    AKR1B10-IN-1

    		Aldose Reductase Cancer
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells .
    AKR1B10-IN-1
  • HY-155474
    Me4Phen

    		Apoptosis Cancer
    Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .
    Me4Phen
  • HY-19543
    Brusatol
    30+ Cited Publications

    NSC 172924

    		 Keap1-Nrf2 Apoptosis Cancer
    Brusatol (NSC?172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .
    Brusatol
  • HY-117952
    L 743310

    		Neurokinin Receptor Neurological Disease
    L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis .
    L 743310
  • HY-120436
    RM 49

    		Drug Derivative Cancer
    RM 49 is the derivative of Mitomycin C (HY-13316). RM 49 exhibits cytotoxicity in SCLC and NSCLC lung cancer cells with IC50 of 0.01-0.5 μg/mL. RM 49 exhibits high relative antitumor activity in compared with Mitomycin C, Cisplatin (HY-17394), Carboplatin (HY-17393) and Doxorubicin (HY-15142) .
    RM 49
  • HY-156368
    RIPK3-IN-4

    		RIP kinase Inflammation/Immunology
    RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .
    RIPK3-IN-4
  • HY-W010342
    6-Aminonicotinamide
    5+ Cited Publications

    		 NADPH Oxidase Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide
  • HY-122552
    Chrysotobibenzyl

    		Integrin Cancer
    Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .
    Chrysotobibenzyl
  • HY-120139
    KMH-233
    1 Publications Verification

    		 Amino acid Transporter Cancer
    KMH-233, a potent, reversible and selective inhibitor of l-type amino acid transporter LAT1/SLC7A5, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 μM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 μM) .
    KMH-233
  • HY-P1380A
    Difopein TFA

    		Apoptosis Cancer
    Difopein TFA, a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein TFA is not cell permeable. Difopein TFA leads to induction of apoptosis and enhances the ability of Cisplatin (HY-17394) to kill cells .
    Difopein TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: